Zevra Therapeutics reports Q1 EPS 60c, consensus 8c

Reports Q1 revenue $36.2M, consensus $31.96M. In Q1, the company received $40.5M of the $45M in net proceeds from the sale of the SDX portfolio. “Our results demonstrate the differentiated model we have built to drive growth and profitability while expanding access to high-quality, affordable care through a wide-network PPO,” said Clover Health CEO Andrew Toy. “During the first quarter, we delivered strong performance across key metrics, driven by deeper clinical engagement, with Clover Assistant supporting earlier intervention and better outcomes for our members. As we continue to scale our technology to reach more members, we expect to achieve our first full year of GAAP Net Income profitability in 2026.”